Overview

A Pharmacokinetic Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-007)

Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to characterize the pharmacokinetics of MK-1602 in the treatment of acute migraine, including the influence of demographic and other variables on MK-1602 pharmacokinetics, and to evaluate the relationship between MK-1602 concentrations and efficacy of the drug.
Phase:
Phase 2
Details
Lead Sponsor:
Allergan